Lu Yanxin, Kwintkiewicz Jakub, Liu Yang, Tech Katherine, Frady Lauren N, Su Yu-Ting, Bautista Wendy, Moon Seog In, MacDonald Jeffrey, Ewend Matthew G, Gilbert Mark R, Yang Chunzhang, Wu Jing
Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Cancer Res. 2017 Apr 1;77(7):1709-1718. doi: 10.1158/0008-5472.CAN-16-2773. Epub 2017 Feb 15.
Mutations in isocitrate dehydrogenase () are the most prevalent genetic abnormalities in lower grade gliomas. The presence of these mutations in glioma is prognostic for better clinical outcomes with longer patient survival. In the present study, we found that defects in oxidative metabolism and 2-HG production confer chemosensitization in IDH1-mutated glioma cells. In addition, temozolomide (TMZ) treatment induced greater DNA damage and apoptotic changes in mutant glioma cells. The PARP1-associated DNA repair pathway was extensively compromised in mutant cells due to decreased NAD availability. Targeting the PARP DNA repair pathway extensively sensitized IDH1-mutated glioma cells to TMZ. Our findings demonstrate a novel molecular mechanism that defines chemosensitivity in IDH-mutated gliomas. Targeting PARP-associated DNA repair may represent a novel therapeutic strategy for gliomas. .
异柠檬酸脱氢酶(IDH)突变是低级别胶质瘤中最常见的基因异常。胶质瘤中这些突变的存在预示着更好的临床结果和更长的患者生存期。在本研究中,我们发现氧化代谢缺陷和2-羟基戊二酸(2-HG)生成赋予IDH1突变的胶质瘤细胞化学敏感性。此外,替莫唑胺(TMZ)处理在突变的胶质瘤细胞中诱导了更大的DNA损伤和凋亡变化。由于烟酰胺腺嘌呤二核苷酸(NAD)可用性降低,PARP1相关的DNA修复途径在突变细胞中受到广泛损害。靶向PARP DNA修复途径使IDH1突变的胶质瘤细胞对TMZ高度敏感。我们的研究结果证明了一种定义IDH突变胶质瘤化学敏感性的新分子机制。靶向PARP相关的DNA修复可能代表一种治疗胶质瘤的新策略。